Study of ALN-HTT02 for Huntington's disease
Part of Brain & nervous system, Genetic & congenital, Mental health clinical trials.
This trial tests an experimental drug called ALN-HTT02 for people with Huntington's disease. The goal is to see if it can help manage symptoms. Participants must have stage 2 or early stage 3 Huntington's disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have stage 2 or early stage 3 Huntington's disease
- You must not have other serious brain or nerve conditions besides Huntington's
- You must not have a weakened immune system due to infections, medical conditions, or treatments
- Your liver function tests must be within normal range
- Your kidney function must be above a certain level
- You cannot have taken any experimental drug in the past year
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This first-in-human study tests whether SRP-1005, a new drug, is safe and tolerable in people with early Huntington's disease. The drug is designed to reduce levels of a harmful protein in the brain that causes Huntington's symptoms.
This is an early-phase study testing a new drug (RG6496) for people with Huntington's disease. The study will check the drug's safety and how the body processes it, and it requires two doses given about 6 months apart.
This trial tests a new radioactive tracer called [11C]CHDI-00491009 that may show mutant huntingtin protein in the brain using a PET scan. It aims to find out if the tracer is safe and helps see Huntington's disease changes. If you have early-stage Huntington's or are a healthy volunteer, you may be able to join.
This trial tests a new drug called SKY-0515 in people with Huntington's disease. The goal is to see if it can safely improve symptoms or slow the disease down.
This trial tests a gene therapy called SPK-10001 for people with early-stage Huntington's disease. It aims to slow the progression of symptoms by targeting the genetic cause of the disease.
This trial tests if a vitamin B3-like supplement, nicotinamide riboside, can help people with early to mid-stage Huntington's disease. You will be randomly assigned to take the supplement or a placebo to see if it slows the disease.
Hear when a new Huntington's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.